Illumina (ILMN) returns

Life Sciences Tools & Services · NASDAQ · Health Care

$202.61 +2.33% Close Nov 17, 2026 Live

TrendArc score 50 of 100 · Health 8.6 · Momentum 2.8 · Moat 4.6 · scored Nov 17, 2026 · How the score works

Illumina returns over 10 years

$1,000 invested in Illumina ten years ago was worth $1,553 at the close on November 17, 2026, with dividends reinvested: an average return of 4.5% a year. The same $1,000 in the S&P 500 (SPY) became $3,919.

ILMN, $1,000 investedS&P 500 (SPY)
$2,000$4,000
20172019202120232025

Total return by period

With dividends reinvested, to the close on Nov 17, 2026. A year means 365 days.
PeriodTotal returnA year, on average$1,000 becameS&P 500 (SPY)
1 month -22.8% — $771.73 -4.0%
3 months +4.9% — $1,049 -5.0%
Year to date +54.5% — $1,545 +8.2%
1 year +68.7% — $1,687 +11.2%
3 years +120.8% +30.2% $2,208 +68.5%
5 years -44.8% -11.2% $551.55 +67.3%
10 years +55.3% +4.5% $1,553 +291.9%

Illumina return by calendar year

YearILMNS&P 500 (SPY)Difference
2026 to date +54.5% +8.2% +46.2%
2025 -1.8% +17.7% -19.6%
2024 -1.3% +24.9% -26.2%
2023 -31.1% +26.2% -57.3%
2022 -46.9% -18.2% -28.7%
2021 +2.8% +28.7% -25.9%
2020 +11.5% +18.4% -6.8%
2019 +10.6% +31.2% -20.6%
2018 +37.3% -4.6% +41.8%
2017 +70.6% +21.7% +48.9%
2016 -33.3% +12.0% -45.3%

Illumina returns against its peers

Total return with dividends reinvested, to the close on Nov 17, 2026.
Company1 year3 years5 years10 years
IlluminaILMN +68.7%+120.8%-44.8%+55.3%
Mettler ToledoMTD +23.3%+63.3%+11.7%+309.3%
IQVIAIQV +19.2%+25.8%-2.6%+224.1%
WatersWAT +19.0%+71.8%+31.0%+223.9%
Agilent TechnologiesA +20.1%+55.6%+10.5%+304.9%
Charles River LaboratoriesCRL +104.1%+75.7%-15.5%+350.6%
Bio-TechneTECH +24.6%+20.9%-39.7%+192.0%
Peer median+21.7%+59.5%+3.9%+264.5%
S&P 500 (SPY)+11.2%+68.5%+67.3%+291.9%

Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.

See also: ILMN financials · ILMN valuation

No forecast, no recommendation. This page describes Illumina from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.